GLOBAL RESEARCH ARCHIVE
Roche "2Q/1H26 Results Preview" (Buy) Weston
Research evidence excerpt
Roche "2Q/1H26 Results Preview" (Buy) Weston
at all. The recipient should carefully read this document in its
entirety and not draw inferences or conclusions from the rating alone. By receiving this document, the recipient acknowledges and agrees with the intended
purpose described above and further disclaims any expectation or belief that the information constitutes investment advice to the recipient or otherwise purports
to meet the investment objectives of the recipient. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain
categories of investors.
Options, structured derivative products and futures (including OTC derivatives) are not suitable for all investors. Trading in these instruments is considered risky
and may be appropriate only for sophisticated investors. Prior to buying or selling an option, and for the complete risks relating to options, you must receive a
copy of "The Characteristics and Risks of Standardized Options." You may read the document at https://www.theocc.com/publications/risks/riskchap1.jsp or ask
your salesperson for a copy. Various theoretical explanations of the risks associated with these instruments have been published. Supporting documentation for
any claims, comparisons, recommendations, statistics or other technical data will be supplied upon request. Past performance is not necessarily indicative of
future results. Transaction costs may be significant in option strategies calling for multiple purchases and sales of options, such as spreads and straddles. Because
of the importance of tax considerations to many options transactions, the investor considering options should consult with his/her tax advisor as to how taxes
The English excerpt is extracted automatically from the cited source page and may contain layout or recognition errors. It is never batch translated.
Open report viewer